PROCEPT BioRobotics (NASDAQ:PRCT) Releases Earnings Results, Misses Expectations By $0.01 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings results on Tuesday. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01), Zacks reports. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. PROCEPT BioRobotics updated its FY 2025 guidance to EPS and its FY 2025 guidance to EPS.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT traded down $2.44 during trading on Tuesday, reaching $62.71. The company’s stock had a trading volume of 1,505,426 shares, compared to its average volume of 891,634. PROCEPT BioRobotics has a twelve month low of $45.20 and a twelve month high of $103.81. The business’s fifty day moving average price is $76.05 and its 200-day moving average price is $80.01. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -32.16 and a beta of 1.03.

Insider Transactions at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 28,092 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the sale, the executive vice president now owns 52,472 shares of the company’s stock, valued at $5,096,605.36. The trade was a 34.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the sale, the chief executive officer now owns 152,762 shares in the company, valued at approximately $14,851,521.64. This represents a 14.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 80,935 shares of company stock worth $7,882,089 over the last 90 days. 17.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Morgan Stanley initiated coverage on shares of PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an “overweight” rating and a $105.00 target price for the company. Wells Fargo & Company reissued an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Jefferies Financial Group began coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a “hold” rating and a $95.00 price objective for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and a consensus target price of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).